NEW
Font size
WorksheetsPatient Profiles Quiz
Total questions: 25
Worksheet time: 25mins
Which drug modulates PPARγ, an established target in insulin resistance and metabolic syndrome?
Bisoprolol
Telmisartan
Both
Neither
In patients with hypertension and diabetes, Telmisartan is beneficial because it:
Reduces blood pressure only
Improves insulin sensitivity and lipid profiles
Has no effect on metabolic parameters
Increases glucose levels
What is the primary benefit of Bisoprolol in patients with mild to moderate hypertension?
Metabolic neutrality
Lipid profile improvement
Blood pressure reduction only
Kidney protection
In patients with stage 3-5 CKD hypertension, Bisoprolol has been shown to:
Significantly reduce blood pressure and heart rate with good tolerance
Worsen renal function
Increase microalbuminuria
Not be safe for use
Telmisartan's role in hypertensive patients with compelling indications such as post-MI is:
Not effective
Demonstrated to reduce cardiovascular morbidity and mortality
Only reduces blood pressure, not cardiovascular events
Causes adverse renal effects
The ONTARGET trial showed Telmisartan effectively reduces:
Blood glucose only
CV morbidity and mortality
Lipid levels exclusively
Microalbuminuria only
For young hypertensive patients with high resting heart rate, Bisoprolol is considered because it:
Has no effect on heart rate
Is superior in reducing BP and HR among selective β-blockers
Worsens left ventricular hypertrophy
Causes sexual dysfunction
In hypertensive patients with metabolic syndrome, Telmisartan helps by:
Modulating PPARγ and improving insulin resistance
Increasing triglyceride levels
Causing weight gain
Increasing blood pressure
What is a common effect of Bisoprolol on lipid and glucose levels?
Increases glucose and triglycerides
Reduces glucose, cholesterol, and triglycerides
Has no effect on metabolic parameters
Worsens lipid profile
In hypertensive patients with CKD, Bisoprolol is considered:
Unsafe for use
Effective for preservation of renal performance and safe with long-term benefits
Ineffective in reducing blood pressure
Only useful for heart rate control without renal benefits
Combination therapy with RAS blockers and β-blockers in hemodialysis patients:
Is associated with worse cardiovascular survival
Is associated with better cardiovascular survival
Has no impact on survival
Is contraindicated
In patients with a high resting heart rate (>80 bpm), the addition of:
A calcium channel blocker
A β-blocker such as Bisoprolol
A diuretic
No addition is needed
Telmisartan's once-daily dosing provides superior control of:
Only systolic blood pressure
Systolic and diastolic blood pressure during the last 6 hours of the dosing interval
Blood glucose levels
Lipid levels
Bisoprolol is preferred over other selective β-blockers because it:
Has no effect on blood pressure
Is more effective in reducing BP and HR, and has fewer sexual side effects
Increases lipid levels
Causes significant metabolic changes
In patients with hypertension and atrial fibrillation, which medication has demonstrated cardiovascular prevention benefits?
Bisoprolol
Telmisartan
Both
Neither
Which statement best describes the metabolic effects of Bisoprolol?
It worsens lipid and glucose metabolism
It reduces BP, HR, glucose, cholesterol, and triglycerides in hypertensive men
It solely reduces blood pressure without metabolic effects
It is metabolically neutral only in high doses
What is one of Telmisartan's renal benefits?
Causes progression of microalbuminuria
Prevents progression of microalbuminuria
Has no effect on renal function
Worsens renal endothelial function
Why is Bisoprolol considered safe for patients with stage 3-5 CKD?
It significantly worsens renal function
It significantly reduces BP and heart rate with good tolerance
It is ineffective in blood pressure control
It causes microalbuminuria
What is a key factor in considering Bisoprolol for a young hypertensive patient?
It does not affect heart rate
It reduces BP and heart rate, and reverses left ventricular hypertrophy
It is only effective in older patients
It causes sexual dysfunction
In the context of cardiovascular risk reduction, Telmisartan is shown to:
Increase CV events
Reduce MI and stroke significantly
Worsen lipid profiles
Be ineffective in high CV risk patients
The effectiveness of Bisoprolol in decreasing the risk of mortality in patients with CAD is supported by:
RWE 2018 showing a 55% reduction
Only animal studies
No evidence available
High rates of adverse effects
In hypertensive patients with diabetes or dyslipidemia, Telmisartan mainly:
Worsens lipid profiles
Has no impact
Effectively reduces BP and improves insulin sensitivity
Causes hypoglycemia
In patients with hypertension and microalbuminuria, Telmisartan:
Prevents progression of microalbuminuria
Has no renal benefits
Worsens renal function
Is contraindicated
Telmisartan's cardiovascular prevention effects were demonstrated in which major trial?
PATIENT study
ONTARGET study
ALLHAT trial
SPRINT trial
What does this image represent
Glucose Metabolism
Reducing Peripheral Vascular Resistance
Comprehensive Neuroendocrine Blockade
All of the above
